A Study of TRC003 in the Treatment of Patients With Progressive PSMA-positive mCRPC
A Prospective, Open-label, Randomized, Phase 1/2 Study of TRC003 in the Treatment of Patients With Progressive PSMA-positive Metastatic Castration-resistant Prostate Cancer (mCRPC)
C Ray Therapeutics
90 participants
May 22, 2026
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to evaluate safety and tolerability, pharmacokinetics （PK）, efficacy of TRC003 injection in patients with progressive PSMA-positive mCRPC who have been treated with androgen receptor pathway inhibitor (ARPI) or taxane-based chemotherapy. We plan to recruit 90 participants who will be randomly assigned to 1 of 3 dose cohorts (30 cases per dose cohort) with up to 6 cycles of treatment in this study.
Eligibility
Inclusion Criteria9
- Participants must have the ability to understand and sign ICF.
- Participants must have histological, and/or cytological confirmation of adenocarcinoma of the prostate.
- Participants must have progressive mCRPC after treatment of ARPI or taxane-based chemotherapy.
- Participant must have been diagnosed with mCRPC with documented progressive disease.
- Participants must have prior orchiectomy and/or ongoing androgen-deprivation therapy with a castrate level of serum testosterone (< 50 ng/dL or < 1.7 nmol/L).
- Participants must have one or more PSMA-positive lesions whose PSMA uptake (SUVmax) is more than 2 fold of the blood pool.
- Participants with an ECOG performance status of 0 - 2.
- Participants must have adequate organ function
- For participants who have partners of childbearing potential: Partner and/or patient must use a method of birth control with adequate barrier protection, deemed acceptable by the principal Investigator during the study and for 6 months after last investigational product administration.
Exclusion Criteria10
- Participants with mixed histology of prostate cancer (e.g., neuroendocrine).
- Any FDG-positive and PSMA-negative target lesions.
- Any investigational agents and other concurrent chemotherapy, targeted therapy, biologic agents, immunotherapy, radioligand therapy (androgen-deprivation therapy excepted) within 28 days or 5 half-lives prior to day of administration, whichever is longer.
- Previous treatment with any conventional external beam radiotherapy including hemi-body radiation within 6 weeks before enrollment.
- Previous bone-targeted therapy cannot be taken with a stable dose within 4 weeks before enrollment.
- Known hypersensitivity to the components of the study therapy or its analogs.
- Transfusion for the sole purpose of making a participant eligible for study inclusion within 28 days before administration.
- A superscan as seen in the baseline bone scan.
- Concurrent serious (as determined by the Investigator) medical conditions.
- Diagnosed with other malignancies that are expected to alter life expectancy or may interfere with disease assessment.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
TRC003 is a radioligand therapeutic agent indicated for the treatment of adult patients with prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer. TRC003 is a 225Ac-labeled novel molecule for targeted alpha therapy (TAT), which delivers alpha-particle radiation specifically to prostate cancer cells expressing PSMA. Inside the body, it attaches itself to PSMA on the cell surface of the prostate cancer cells and emits radiation to kill them.
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07567521